Aztreonam is a Small Molecule owned by Bristol-Myers Squibb, and is involved in 1 clinical trial, which is ongoing.

Aztreonam exhibits bactericidal action by inhibiting bacterial cell wall synthesis due to its high affinity for penicillin-binding protein (PBP) of gram-negative bacteria. It is highly resistant to hydrolysis by beta lactamases.

The revenue for Aztreonam is expected to reach a total of $100m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Aztreonam NPV Report.

Aztreonam is currently owned by Bristol-Myers Squibb.

Aztreonam Overview

Aztreonam (Azactam) is a monobactam derivative that acts as an antibiotic. It is formulated as injectable solution and injectable powder for solution, for intravenous or intramuscular route of administration. It is indicated for the treatment of skin and skin structure infections by s.pneumoniae, peritonitis,interstitial cystitis (painful bladder syndrome), septicaemia, cellulitis,gonorrhea,pelvic inflammatory disease (pelvic infections), complicated intra-abdominal infections, pneumonia, urinary tract infections, pyelonephritis, respiratory tract infections, bronchitis, endometriosis, gram-negative bacterial infections, cystitis, bacteriuria, neisseria gonorrhoeae infections, uncomplicated urethral and anorectal infections of gonorrhea, lower respiratory tract infections, bacteremia, prosthetic joint infections, skin and soft tissue infections and abscess, wounds.

Bristol-Myers Squibb Overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.

Quick View – Aztreonam

Report Segments
  • Innovator (NME)
Drug Name
  • Aztreonam
Administration Pathway
  • Intramuscular
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Ear Nose Throat Disorders
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
  • Musculoskeletal Disorders
  • Ophthalmology
  • Respiratory
  • Women’s Health
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.